In particular, several studies carried out in different animal models provided a consistent body of evidence that definitely demonstrated the significant anti-obesity and antidiabetic activities of this PTP1B inhibitor, supporting its potential as an agent for the treatment of metabolic disorders. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.